Cytokine Storm Drugs Move from CAR T to COVID-19

Abstract Early reports suggest that tocilizumab, an IL6 receptor–blocking antibody used to manage toxicities associated with chimeric antigen receptor T-cell therapy, may help control cytokine storms in people infected with COVID-19. Preliminary data from randomized trials are less clear-cut.